Parabilis Medicines surged to a blockbuster Nasdaq debut, raising about $670 million as the company drives its tumor-focused pipeline forward. The listing follows another record set by obesity biotech Kailera Therapeutics’ roughly $625 million IPO earlier in the year. The renewed IPO momentum has restarted attention on biotech’s access to public capital after years of drought, with analysts pointing to pent-up venture and Big Pharma funding deployed post-pandemic. Industry commentary suggests the IPO reopening is tied to both deal activity in M&A and a backlog of venture-backed programs seeking liquidity. For investors, the message is clear: even amid uncertain macro conditions and a still-evolving regulatory leadership landscape, the market is rewarding clinical narratives and scalable platforms with rapid capital inflows.